Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (SHPD002)
A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer
Sponsor: RenJi Hospital
A PHASE2/PHASE3 clinical study on Inflammatory Breast Cancer and Invasive Ductal Breast Cancer, this trial is ongoing. The trial is conducted by RenJi Hospital and has accumulated 10 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Unknown Status → Active Not Recruiting
-
Nov 2022 — Sep 2023 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Apr 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RenJi Hospital
For direct contact, visit the study record on ClinicalTrials.gov .